Risk of Cerebrovascular Adverse Events and Death in Elderly Patients With Dementia When Treated With Antipsychotic Medications: A Literature Review of Evidence

被引:100
|
作者
Mittal, Vikrant [2 ]
Kurup, Lekshminarayana
Williamson, Deena [3 ]
Muralee, Sunanda [1 ]
Tampi, Rajesh R. [1 ,3 ]
机构
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA
[2] BJC Healthcare Syst, Farmington, MO USA
[3] Masonicare, Wallingford, CT USA
关键词
dementia; cerebrovascular adverse events; death; antipsychotics; PLACEBO-CONTROLLED TRIALS; NURSING-HOME RESIDENTS; ATYPICAL ANTIPSYCHOTICS; ALZHEIMERS-DISEASE; RETROSPECTIVE COHORT; 2ND-GENERATION ANTIPSYCHOTICS; PSYCHOLOGICAL SYMPTOMS; RISPERIDONE TREATMENT; BEHAVIORAL SYMPTOMS; RANDOMIZED-TRIAL;
D O I
10.1177/1533317510390351
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Behavioral and Psychological Symptoms of Dementia (BPSD) are increasingly recognized as a major risk factor for caregiver burden, institutionalization, greater impairment in activities of daily living (ADLs), more rapid cognitive decline, and a poorer quality of life. BPSD contribute significantly to the direct and indirect costs of caring for patients with dementia even after adjusting for the severity of cognitive impairment and other co-morbidities. Research on these symptoms has indicated a complex interplay between the biological, psychological and social factors involved in the disease process. Although some psychotropic medications have shown modest efficacy in the treatment of these behaviors, their use has generated controversy due to increasing recognition of the side effects of these medications especially the antipsychotic medications. In this review, we examine the risk of cerebrovascular adverse events (CVAEs) and death with antipsychotic medications when used to treat elderly patients with dementia.
引用
收藏
页码:10 / 28
页数:19
相关论文
共 50 条
  • [31] Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
    Hou, Yan-Li
    Wang, Di-Ya
    Hu, Jie-Xuan
    Tian, Ru-Yue
    Wang, Wei
    Su, Qiang
    Li, Hongyang
    Wang, Yan-Ling
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (06) : 1449 - 1459
  • [32] Impact of biologic therapies on risk of adverse cardiovascular events in patients with Ankylosing Spondylitis or Psoriatic Arthritis: a systematic literature review
    Magiouf, K. S.
    Fragiadaki, K.
    Charpidou, A.
    Syrigos, A.
    Kotteas, E.
    Kourlaba, G.
    [J]. ARP RHEUMATOLOGY, 2023, 2 (01): : 53 - 63
  • [33] Risk factors for drug-treated major adverse cardio-cerebrovascular events in patients on primary preventive statin therapy: A retrospective cohort study
    Steenhuis, Dennis
    de Vos, Stijn
    Bos, Jens H. J.
    Hak, Eelko
    [J]. PREVENTIVE MEDICINE REPORTS, 2023, 34
  • [34] Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
    Kim, In Young
    Eun, Yeonghee
    Kim, Hyungjin
    Ahn, Joong Kyong
    Park, Eun-Jung
    Jeon, Chan Hong
    Kim, Jinseok
    Cha, Hoon-Suk
    Koh, Eun-Mi
    Lee, Jaejoon
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [35] Hypertensive patients treated with beta blockers prior to surgery are at increased risk of major adverse cardiovascular events and death a nationwide cohort study
    Joergensen, M. E.
    Gislason, G. H.
    Torp-Pedersen, C.
    Andersson, C.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1045 - 1045
  • [36] Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review
    Konstantina, Thomopoulou
    Konstantinos, Rounis
    Anastasios, Koutsopoulos
    Anastasi, Mala
    Eleni, Lagoudaki
    Ioannis, Sougklakos
    Sofia, Agelaki
    Dimitris, Mavroudis
    [J]. LUNG CANCER, 2019, 135 : 29 - 32
  • [37] Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis
    Shang, Yan Hong
    Zhang, Yu
    Li, Jing Hua
    Li, Peng
    Zhang, Xi
    [J]. IMMUNOTHERAPY, 2017, 9 (03) : 261 - 272
  • [38] Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis
    Dong, Jiawei
    Meng, Xiangqi
    Li, Siyi
    Chen, Qun
    Shi, Lei
    Jiang, Chuanlu
    Cai, Jinquan
    [J]. WORLD NEUROSURGERY, 2019, 130 : E236 - E243
  • [39] The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis
    Yang, Yan-Li
    Xiang, Zi-Jian
    Yang, Jing-Hua
    Wang, Wen-Jie
    Xiang, Ruo-Lan
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [40] Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis
    Xiaoqing Li
    Rongzhong Huang
    Zhongye Xu
    [J]. Scientific Reports, 5